Home - Products - Angiogenesis - EGFR - Lidocaine Hydrochloride hydrate

Lidocaine Hydrochloride hydrate

CAS No. 6108-05-0

Lidocaine Hydrochloride hydrate( —— )

Catalog No. M15297 CAS No. 6108-05-0

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 49 In Stock
100MG 63 In Stock
200MG 88 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lidocaine Hydrochloride hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.
  • Description
    Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.(In Vitro):Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation.Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10?nM and treatment time 48?hours.Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate.Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly.(In Vivo):Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block.
  • In Vitro
    Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation. Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10?nM and treatment time 48?hours. Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate. Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly. Cell Proliferation Assay Cell Line:The human gastric cancer cell line MKN45 Concentration:10?nM Incubation Time:48 hours Result:Decreased significantly cell proliferation.Cell Viability Assay Cell Line:The human gastric cancer cell line MKN45 Concentration:1, 5 and 10?nMIncubation Time:24, 48, 72 hours Result:Inhibited MKN45 cell viability.Apoptosis Analysis Cell Line:The human gastric cancer cell line MKN45 Concentration:10?nM Incubation Time:48 hours Result:Increased significantly the apoptotic cell rate.Western Blot Analysis Cell Line:The human gastric cancer cell line MKN45 Concentration:10?nM Incubation Time:48 hours Result:Down-regulated Cyclin D1 and up-regulated p21 expression significantly.
  • In Vivo
    Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR| Sodium Channel
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    6108-05-0
  • Formula Weight
    288.82
  • Molecular Formula
    C14H22N2O·HCl·H2O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O.Cl.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sheets PL, et al. J Physiol. 2007 Jun 15;581(Pt 3):1019-3
molnova catalog
related products
  • AZD8931 diFuMaric ac...

    AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.

  • NRC-2694

    NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.

  • Tyrphostin A25

    Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.3 μM for GPR35.